News Content
Teriparatide is the active fragment of recombinant human parathyroid hormone. It increases bone mass by stimulating osteoblast activity and is mainly used for osteoporosis in postmenopausal women and men at high risk of fracture, as well as for the treatment of glucocorticoid-induced osteoporosis. Its 24-month treatment limit is not based on efficacy attenuation, but rather on safety considerations: animal studies have shown that long-term high-dose use of teriparatide increases the incidence of osteosarcoma in rats in a dose-dependent manner. Although the association of related risks in human use is not yet clear, strict treatment duration limits are still set in clinical practice to avoid potential harm.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-teriparatide.html
Furthermore, this drug is strictly contraindicated in high-risk groups such as adolescents with unclosed epiphyses and those with a history of osteosarcoma. In clinical use, teriparatide is recommended to be administered subcutaneously at a dose of 20 μg daily. During treatment, calcium and vitamin D supplementation should be given according to dietary intake. Patients with moderate renal or hepatic impairment should use this medication with caution. It is important to note that the osteoproliferative effect of teriparatide diminishes rapidly after discontinuation. Without sequential treatment, the increased bone density may be lost again. Therefore, after discontinuation, patients should promptly switch to anti-resorption drugs such as bisphosphonates or denosumab to prolong the therapeutic effect.
Current clinical studies have confirmed that within a standard 24-month treatment course, teriparatide can significantly reduce the risk of vertebral and non-vertebral fractures in patients with osteoporosis, and the benefits far outweigh the potential risks. Strict adherence to the treatment course is crucial for its safe clinical use.
